These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 18408882

  • 1. Time to insulin in type-2 diabetes: high hurdles or Santiago way?
    Rotella CM, Pala L.
    Acta Diabetol; 2008 Jun; 45(2):67-74. PubMed ID: 18408882
    [Abstract] [Full Text] [Related]

  • 2. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX.
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [Abstract] [Full Text] [Related]

  • 3. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S, Collier A, Elhadd T, Malik I.
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [Abstract] [Full Text] [Related]

  • 4. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL.
    Diabetes Educ; 2008 Jun; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [Abstract] [Full Text] [Related]

  • 5. [Incretins in the treatment of diabetes].
    Bulum T, Smircić-Duvnjak L, Car N, Metelko Z.
    Lijec Vjesn; 2008 Jun; 130(7-8):195-200. PubMed ID: 18979908
    [Abstract] [Full Text] [Related]

  • 6. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 7. Protection of pancreatic beta-cells: is it feasible?
    Bonora E.
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [Abstract] [Full Text] [Related]

  • 8. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF.
    Diabetes Educ; 2008 Jan; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [Abstract] [Full Text] [Related]

  • 9. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 10. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK.
    J Am Pharm Assoc (2003); 2009 Jun; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [Abstract] [Full Text] [Related]

  • 11. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH.
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [Abstract] [Full Text] [Related]

  • 12. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
    Kendall DM, Cuddihy RM, Bergenstal RM.
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S329-39. PubMed ID: 19580952
    [Abstract] [Full Text] [Related]

  • 13. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
    Dagogo-Jack S, Santiago JV.
    Arch Intern Med; 1997 Sep 08; 157(16):1802-17. PubMed ID: 9290539
    [Abstract] [Full Text] [Related]

  • 14. Weight gain during insulin therapy in patients with type 2 diabetes mellitus.
    Heller S.
    Diabetes Res Clin Pract; 2004 Sep 08; 65 Suppl 1():S23-7. PubMed ID: 15315867
    [Abstract] [Full Text] [Related]

  • 15. Insulin treatment and the problem of weight gain in type 2 diabetes.
    Carver C.
    Diabetes Educ; 2006 Sep 08; 32(6):910-7. PubMed ID: 17102158
    [Abstract] [Full Text] [Related]

  • 16. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J.
    Consult Pharm; 2009 Jun 08; 24 Suppl B():11-7. PubMed ID: 19555131
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb 08; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 18. Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success?
    Frezza EE.
    Obes Surg; 2004 Aug 08; 14(7):999-1005. PubMed ID: 15329192
    [Abstract] [Full Text] [Related]

  • 19. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M, Rayfield EJ.
    Mt Sinai J Med; 2009 Jun 08; 76(3):244-56. PubMed ID: 19421968
    [Abstract] [Full Text] [Related]

  • 20. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug 08; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.